Effect of oral supplementation with branched-chain amino acid (BCAA) during radiotherapy in patients with hepatocellular carcinoma: A double-blind randomized study

Cancer Research and Treatment

Volumn 43, Issue 1, 2011, Pages 24-31

  Lee, Ik Jae ^a   Seong, Jinsil ^a   Bae, Jung Im ^a   You, Sei Hwan ^a   Rhee, Yumie ^a   Lee, Jong Ho ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Branched chain amino acids; Hepatocellular carcinoma; Radiotherapy

Indexed keywords

EID: 84859122738     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2011.43.1.24     Document Type: Article

References (25)

1. el-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001;5:87-107, vi.
2. Annual report on the cause of death statistics [Internet]. Daejeon: Korea National Statistical Office; 2009 [cited 2010 Mar 4]. Available from: http://www.kosis.kr.
3. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002;235:466-86.
4. Cochrane AM, Murray-Lyon IM, Brinkley DM, Williams R. Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer. 1977;40:609-14.
5. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200-8.
6. Lawrence TS, Tesser RJ, ten Haken RK. An application of dose volume histograms to the treatment of intrahepatic malignancies with radiation therapy. Int J Radiat Oncol Biol Phys. 1990;19:1041-7.
7. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-22.
8. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys. 1992;23:781-8.
9. Robertson JM, McGinn CJ, Walker S, Marx MV, Kessler ML, Ensminger WD, et al. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys. 1997;39:1087-92.
10. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY, et al. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:393-7.
11. Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1143-50.
12. Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int. 2005;25:1189-96.
13. Lee IJ, Seong J, Shim SJ, Han KH, Chon CY. Reappraisal of risk factors predicting liver complications from radiotherapy for hepatocellular carcinoma. Korean J Hepatol. 2006;12:420-8.
14. Cheng JC, Wu JK, Huang CM, Huang DY, Cheng SH, Lin YM, et al. Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol. 2002;63:41-5.
15. Liang SX, Zhu XD, Xu ZY, Zhu J, Zhao JD, Lu HJ, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys. 2006;65:426-34.
16. Nompleggi DJ, Bonkovsky HL. Nutritional supplementation in chronic liver disease: an analytical review. Hepatology. 1994;19:518-33.
17. Fan ST, Lo CM, Lai EC, Chu KM, Liu CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med. 1994;331:1547-52.
18. Meng WC, Leung KL, Ho RL, Leung TW, Lau WY. Prospective randomized control study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust N Z J Surg. 1999;69:811-5.
19. Muto Y, Yoshida T, Sato S, Suzuki K, Okada H, Hayashi S, et al. Effect of oral administration with branched-chain amino acid granules (BCAA-G) in patients with liver cirrhosis: a clinical study. JJPEN. 1989;11:1119-34.
20. Lee IJ, Seong J, Shim SJ, Han KH. Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:154-8.
21. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a doubleblind, randomized trial. Gastroenterology. 2003;124:1792-801.
22. Song KH, Kim MS, Han KH, Lee KS, Chon CY, Moon YM, et al. Prospective study on efficacy of oral supplement of branched-chain amino acid granules on the nutritional status of the cirrhotics. Korean J Hepatol. 2001;7:432-8.
23. Nijveldt RJ, Wiezer MJ, Meijer C, Prins HA, Statius Muller MG, Gouma DJ, et al. Major liver resection results in a changed plasma amino acid pattern as reflected by a decreased Fischer ratio which improves by bactericidal/permeability increasing protein. Liver. 2001;21:56-63.
24. Togo S, Tanaka K, Morioka D, Sugita M, Ueda M, Miura Y, et al. Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis. Nutrition. 2005;21:480-6.
25. Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther. 2004;19:779-88.